Tranexamic acid reduces postbypass blood use: A double-blinded, prospective, randomized study of 210 patients
References (26)
- et al.
Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study
Ann Thorac Surg
(1992) - et al.
A prospective randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations
J Thorac Cardiovas Surg
(1986) - et al.
Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency
J Thorac Cardiovasc Surg
(1994) - et al.
Prophylactic tranexamic acid decreases bleeding after cardiac operations
Thorac Cardiovasc Surg
(1990) - et al.
Tranexamic acid (cyclocapron) is not necessary to reduce blood loss after coronary bypass operations
J Thorac Cardiovasc Surg
(1993) - et al.
Noncardiogenic pulmonary edema after cardiopulmonary bypass: an anaphylactic reaction to fresh frozen plasma
Am J Surg
(1984) - et al.
Homologous blood transfusion as a risk factor for postoperative infection after coronary bypass graft operations
J Thorac Cardiovasc Surg
(1992) - et al.
Tranexamic acid and arterial thrombosis
Lancet
(1977) - et al.
Tranexamic acid and intracranial thrombosis
Lancet
(1976) - et al.
Retinal artery occlusion associated with tranexamic acid
Am J Opth
(1988)
Predisposing factors and management of hemorrhage following open-heart surgery
J Cardiovasc Surg
The pathogenesis and control of the hemorrhagic defect in open heart surgery
Surg Gynecol Obstet
Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial
N Engl J Med
Cited by (91)
Emerging materials for hemostasis
2023, Coordination Chemistry ReviewsCitation Excerpt :The antifibrinolytic approaches which suppress plasmin or the binding of plasmin to fibrin have been employed in clinical settings.[13,444,445] Aprotinin, tranexamic acid, and aminocaproic acid are the most widely administered antifibrinolytic pharmaceuticals and have exhibited the ability to minimize blood transfusion needs in surgery.[5,446,447] There are also some hemostatic products which can regulate the level of coagulation factors, instead of modulating directly the level of fibrin, to achieve hemostasis, including fresh frozen plasma abundant in manifold coagulation factors (FII, FV, FVII, FIX, and FX).[448–450]
Combat casualty care and lessons learned from the past 100 years of war
2017, Current Problems in SurgeryCitation Excerpt :A synthetic lysine analog, TXA was found to be a more potent inhibitor of fibrinolysis than its predecessor, ϵ-aminocaproic acid.184 Its clinical use dates back to the 1960s and has been used in the prevention or treatment of bleeding in hereditary coagulopathies, oral surgery, elective cardiac and orthopedic surgeries, ruptured intracranial aneurysms, and gastrointestinal hemorrhage.185-192 However, minimal data existed in 2004 about patient outcomes after the use of TXA in trauma.193
Effect of antifibrinolytic therapy with tranexamic acid on abdominal aortic aneurysm shrinkage after endovascular repair
2014, Journal of Vascular SurgeryCitation Excerpt :In randomized studies, no marked increase in thrombosis after administration of TXA was observed, even in cases in which a thrombotic complication was anticipated and even when the agent was given during an operation.23,24 The plasma TXA concentration found to be effective in obtaining antifibrinolysis has been reported to range from 5 to 15 mg/L, and when 1300 mg TXA was given orally for 5 days, the peak plasma concentration was 16.4 mg/L.24 In Japan, TXA is available in 250-mg capsules, and patients in the TXA group in our study took six of these daily. Overall, these patients had significantly greater aneurysm shrinkage than those not given TXA.
Prehospital use of tranexamic acid for hemorrhagic shock in primary and secondary air medical evacuation
2013, Air Medical JournalCitation Excerpt :We also aggressively prevent further heat loss of our patients and actively warm them when needed using heat blankets, in-line IVF, and blood-warming devices. Finally, although our TXA dosing reflects what is currently reported in the trauma literature, the optimal dose of TXA has yet to be elucidated because higher doses (upward of 10 mg/kg) are often used in other clinical settings.1–6,20–22 In this case series, no patient received doses larger than 1 g, but our guidelines do allow for the use of larger or repeat doses to reflect 10-mg/kg dosing in larger individuals or when out-of-hospital times are prolonged with limited blood product availability or limited means to control hemorrhage during transport.
The effects of tranexamic acid on platelets in patients undergoing cardiac surgery: a systematic review and meta-analysis
2024, Journal of Thrombosis and Thrombolysis
Presented at the Forty-second Annual Meeting of the Southern Thoracic Surgical Association, San Antonio, TX, Nov 9–11, 1995.